Unknown

Dataset Information

0

Upregulation of the Chemokine Receptor CCR2B in Epstein?Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program.


ABSTRACT: CCR2 is the cognate receptor to the chemokine CCL2. CCR2?CCL2 signaling mediates cancer progression and metastasis dissemination. However, the role of CCR2?CCL2 signaling in pathogenesis of B-cell malignancies is not clear. Previously, we showed that CCR2B was upregulated in ex vivo peripheral blood B cells upon Epstein?Barr virus (EBV) infection and in established lymphoblastoid cell lines with the EBV latency III program. EBV latency III is associated with B-cell lymphomas in immunosuppressed patients. The majority of EBV-positive Burkitt lymphoma (BL) tumors are characterized by latency I, but the BL cell lines drift towards latency III during in vitro culture. In this study, the CCR2A and CCR2B expression was assessed in the isogenic EBV-positive BL cell lines with latency I and III using RT-PCR, immunoblotting, and immunostaining analyses. We found that CCR2B is upregulated in the EBV-positive BL cells with latency III. Consequently, we detected the migration of latency III cells toward CCL2. Notably, the G190A mutation, corresponding to SNP CCR2-V64I, was found in one latency III cell line with a reduced migratory response to CCL2. The upregulation of CCR2B may contribute to the enhanced migration of malignant B cells into CCL2-rich compartments.

SUBMITTER: Kozireva S 

PROVIDER: S-EPMC5977232 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program.

Kozireva Svetlana S   Rudevica Zhanna Z   Baryshev Mikhail M   Leonciks Ainars A   Kashuba Elena E   Kholodnyuk Irina I  

Viruses 20180503 5


CCR2 is the cognate receptor to the chemokine CCL2. CCR2⁻CCL2 signaling mediates cancer progression and metastasis dissemination. However, the role of CCR2⁻CCL2 signaling in pathogenesis of B-cell malignancies is not clear. Previously, we showed that CCR2B was upregulated in ex vivo peripheral blood B cells upon Epstein‒Barr virus (EBV) infection and in established lymphoblastoid cell lines with the EBV latency III program. EBV latency III is associated with B-cell lymphomas in immunosuppressed  ...[more]

Similar Datasets

| S-EPMC6071279 | biostudies-literature
2010-05-19 | E-GEOD-13056 | biostudies-arrayexpress
| S-EPMC1595454 | biostudies-literature
2008-10-07 | GSE13056 | GEO
| S-EPMC6606803 | biostudies-literature
| S-EPMC4274971 | biostudies-literature
| S-EPMC3571367 | biostudies-literature
| S-EPMC153638 | biostudies-literature
| S-EPMC5517637 | biostudies-literature
| S-EPMC6954331 | biostudies-literature